Newsletter August 2025
Empowering Oncology Breakthroughs
Discover EPO’s Preclinical Capabilities & Services
EPO (Experimental Pharmacology & Oncology Berlin-Buch GmbH) is a trusted Contract Research Organization (CRO) with over 27 years’ experience in driving innovation in Preclinical Oncology and Immuno-oncology Research and Development.
Founded in 1997, EPO is spin-off from the Max Delbrück Center for Molecular Medicine. Since our inception, we have:
- Completed 20,000+ Client Studies
- Contributed to 600+ Peer-reviewed Publications
- Supported numerous Therapeutics Candidates from Discovery to FDA Approval
- Built long-term collaborations with Global Pharma, Biotech, and Academic Institutions
Whether you're optimizing treatment strategies or validating novel biomarkers, EPO is your partner in accelerating oncology research.
Laboratory Infrastructure & Capabilities
Lab & Facility Highlights:
- 1300 m² (12,000 sqf) of State-of-the-art Laboratory Space
- AAALAC-accredited Animal Facility
- Cleanroom Technology for Sterile Procedures
- Safety Level 2 (S2) containment
Core Laboratory Units:
- Molecular Biology & Protein Analysis – qPCR, qRT-PCR, Western Blotting
- Cell Biology – 2D/3D culture, stem cells, real-time analysis (IncuCyte)
- FACS and Cell Sorting – MACSQuant® Analyzer 16 and Tyto®
- Compound Analytics – Formulation development and QC
- In Vivo imaging – Bioluminescence, Vevo Micro-Ultrasound
- Radiation and Radiopharmaceuticals – MultiRad Efficacy, Biodistribution (Gamma Counting)
- Histology – FFPE Blocking, Sectioning, H&E, IHC, Pathological Examination
- Tumor Bank – Large-scale CDX/PDX/Syngeneic Collection and Data Banking
Robust Oncology Models & Preclinical Services
- 1,000+ PDX Models across 17 tumor types, including hematological malignancy and pediatric tumors.
- 200+ CDX Models with validated endpoints
- Syngeneic Mouse and Rat Models
- Flank, Orthotopic, Disseminated, and Metastasis Models
- Humanized Mouse Models (PBMC, NK, T cells, CD34s) – 20+ years of experience humanizing mice in-house
Our Tailored Services Include:
- Efficacy Studies for Small Molecules, Biologics, ADCs, Cell-based Therapies, and RIT
- PK/PD Profiling and Bioavailability Assessment
- Tox, Safety, MTD and Biodistribution
- Optimization of dosing, scheduling, and drug combinations
- Biomarker Discovery & Validation
- Pathway Analysis to explore drug resistance or sensitivity
- Companion Diagnostic (CDx) Development
By Scientists, For Scientists
Our team of 50+ employees, including 15+ PhDs, brings deep scientific insight and operational flexibility.
Leadership Includes:
- Dr. Jens Hoffmann, CEO
- Dr. Antje Margret Wengner, CSO
- Prof. Dr. Wolfgang Walther, Senior CSO
We are Proud Contributors to Cancer Research Through:
- Partnerships in oncology programs such as: ITCC P4, EFRE, IMI, OncoTrack
- Publications in Leading Scientific Journals
- Presentations at Major Oncology Conferences
Why Partner with EPO?
- End-to-End Custom Study Design – Tailored to your development goals
- Fast Turnaround Times – Agile execution to meet tight timelines
- Transparent, Responsive Communication – Stay informed at every step
- True Scientific Partnership – Collaborative spirit with a focus on impact
Whether you're a Startup, Academic lab, or Global Pharma Company — EPO-Berlin is here to move your science forward.
Get in Touch
For more information, contact us today on to discuss how we can accelerate your therapeutic oncology development.
Best Regards,
Jens Hoffmann (CEO), Wolfgang Walther (CSO), Antje Wengner (CSO)
EPO Berlin-Buch